Rodman & Renshaw Reiterates Buy on Annovis Bio, Maintains $67 Price Target
Portfolio Pulse from Benzinga Newsdesk
Rodman & Renshaw analyst Elemer Piros reiterates a Buy rating on Annovis Bio (NYSE:ANVS) and maintains a $67 price target.
July 02, 2024 | 4:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Rodman & Renshaw analyst Elemer Piros reiterates a Buy rating on Annovis Bio and maintains a $67 price target.
The reiteration of a Buy rating and the maintenance of a $67 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100